Generic Name and Formulations:
Mifepristone 200mg; tabs.
Indications for MIFEPREX:
Termination of intrauterine pregnancy through 70 days gestation, in a regimen with misoprostol.
Adults and Children:
Physician must sign and return Prescriber's Agreement; patient must read and sign Patient Agreement and read Medication Guide. Day 1: mifepristone 200mg as a single oral dose. Day 2 or 3: misoprostol 800mcg buccally within 24–48hrs after mifepristone dose. Day 7–14: confirm that complete termination of pregnancy has occurred by clinical exam or ultrasonographic scan.
Ectopic pregnancy or undiagnosed adnexal mass. IUD in place. Chronic adrenal failure. Prostaglandin allergy. Hemorrhagic disorders. Inherited porphyrias. Concurrent long-term corticosteroid or anticoagulant therapy.
Risk of serious infections or bleeding. To be given only by or under the supervision of physicians who have signed and returned the Prescriber's Agreement; are able to assess gestational age of embryo and diagnose ectopic pregnancy; who have access to facilities for emergency treatment of incomplete abortion, severe bleeding, or resuscitation; and who meet requirements for storage, dose tracking, etc. Do surgical termination if mifepristone and misoprostol fail. Exclude ectopic pregnancy before treatment in patients with an IUD. Procedures to prevent rhesus immunization must be used. Hemostatic disorders. Hypocoagulability. Severe anemia. Pregnancy: treatment failure may result in fetal malformation. Nursing mothers: see full labeling.
See Contraindications. May potentiate CYP3A4 substrates. May be potentiated by ketoconazole, itraconazole, erythromycin, grapefruit juice. May be antagonized by rifampin, dexamethasone, St. John's wort, phenytoin, phenobarbital, carbamazepine.
Nausea, weakness, fever/chills, vomiting, headache, diarrhea, dizziness; uterine bleeding (may be prolonged or severe), cramping; rare: serious bacterial infections, sepsis (may be fatal).
Report serious adverse events by calling (877) 432-7596.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|